Skip to content

Myeloid-Derived Supressor Cells in Cardiac Surgery Patients

Myeloid-Derived Supressor Cells in Uncomplicated vs Complicated Patients After Cardiac Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02902939
Acronym
MyDeCCS
Enrollment
100
Registered
2016-09-16
Start date
2016-09-30
Completion date
2018-07-19
Last updated
2018-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insufficiency; Cardiac, Complicating Surgery, Systemic Inflammatory Response Syndrome

Keywords

Immune Suppression, Inflammatory Response, Cardiac Surgery

Brief summary

Pro- and anti-inflammatory response during the formation of the critical state develops at the same time. Because of its balanced or unbalanced systemic inflammation can be either aborted or able to lead to multiple organ failure. With regard to sepsis, systemic inflammatory response characteristics are well understood, is not achieved in respect of the sterile inflammation. Extracorporeal circulation is a clinical model of systemic inflammatory response due to non-physiological activation of tissue factor in the extracorporeal perfusion, the use of non-pulsatile circulation mode, intentional / unintentional hypothermia, bacterial translocation from the gastrointestinal tract and perfusion deficit. We have proved that the monocytes demonstrate suppressor function, which can be a predictor of complications from cardiac surgery patients. The most important component of the formation of multiple organ failure (MOF) in critically ill patients is immunosuppression. During the study of experimental and clinical tumor growth process scientists has provided a new population of immature myeloid cells (myeloid suppressor cells or suppressor cells of myeloid origin, MDSC). Most of the works have been devoted to the role of MDSC in the development of tumors, where it has been clearly shown that this cell population has an undoubted effect of immune suppression. However, recent studies show that the role of MDSC is not limited to cancer process, but extends to chronic or acute inflammation. The aim of this study is to determine the role of MDSC in the development of immune suppression and complications after heart surgery carried out under cardiopulmonary bypass.

Detailed description

The use of MEC systems can be useful to prevent the MDSC activation after cardiac surgery. The procedures to modulate the cytokines concentration can be useful to prevent the MDSC activation after cardiac surgery.

Interventions

DEVICEminimal extracorporeal circulation (MEC)

We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.

PROCEDUREThe cytokines modulations

We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)

Sponsors

Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. the patients with ischemia heart disease and/or valvular heart disease, 2. signed inform consent, 3. CABG and/or valve replacement/plastic procedures.

Exclusion criteria

1\) congenital heart disease.

Design outcomes

Primary

MeasureTime frame
MOF-free days28 day

Secondary

MeasureTime frame
ICU length of stay28 day
the incidents of infection complications28 day

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026